Immunotherapy in B-Cell Acute Lymphoblastic Leukemia - PubMed
3 months ago
- #immunotherapy
- #cancer treatment
- #B-ALL
- Immunotherapy is increasingly used in B-cell acute lymphoblastic leukemia (B-ALL) for both pediatric and adult patients.
- Four main immunotherapy categories for B-ALL: unconjugated monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), T-cell-engaging antibodies, and CAR T cells.
- Inotuzumab ozogamicin (InO), an ADC, is FDA-approved for relapsed/refractory B-ALL in patients over 1 year and is being tested in upfront settings with chemotherapy.
- T-cell-engaging antibodies, like blinatumomab, are now standard in treating newly diagnosed and relapsed B-ALL, potentially reducing the need for intensive chemotherapy.
- CAR T-cell therapy targets CD19 in relapsed/refractory B-ALL but faces challenges like CAR T-cell persistence loss and antigen escape; newer CAR T cells target CD22 or both CD19 and CD22.
- Immune-based therapies are a mainstay in B-ALL treatment, with ongoing research to improve efficacy and address current limitations.